OMER
Omeros·NASDAQ
--
--(--)
--
--(--)
OMER fundamentals
Omeros (OMER) expects to report earnings on Mar 31, 2026, with estimated revenue of 0 (YoY --), and EPS at -0.57 (YoY -5.56%).
Revenue estimate / YoY
0
--
EPS estimate / YoY
-0.57
-5.56%
Report date
Mar 31, 2026
OMER Earnings Call Summary for Q4,2025
- $2.1B Deal Milestone: Zaltenibart sale to Novo Nordisk includes $240M upfront, $410M development milestones, and high-teens royalties.
- YARTEMLEA Launch Success: 30% of top 80 transplant centers have formulary approval; 24-hour drug delivery meets urgent patient needs.
- Financial Strength: $171.8M cash, debt-free except $70.8M convertible notes. YARTEMLEA expected to be self-sustaining in 2026, cash flow positive by 2027.
- Clinical Impact: First treatment for TA-TMA with no safety restrictions, reducing infection risks vs. C5 inhibitors.
Earnings
EPS
Revenue
Revenue & Expenses
Key Indicators
Omeros (OMER) key financial stats and ratios, covering profitability, financial health, and leverage.
Income Statement
Omeros (OMER)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Balance Sheet
Omeros (OMER)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Cash Flow
Omeros (OMER)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Revenue Breakdown
Where does Omeros (OMER) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Dividend
Track Omeros (OMER) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
What factors drove the changes in Omeros's revenue and profit?What is the revenue and EPS growth rate for Omeros year over year?What were the key takeaways from Omeros's earnings call?What is Omeros's latest dividend and current dividend yield?What guidance did Omeros's management provide for the next earnings period?What is the market's earnings forecast for Omeros next quarter?What does Omeros do and what are its main business segments?Did Omeros beat or miss consensus estimates last quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
